Lensar said today it won FDA 510(k) clearance for its Lensar Laser System with Streamline IV designed to create corneal pockets and flaps used in presbyopia treatments. With the new clearance, the Lensar Laser System is now indicated for use in procedures to implant presbyopic inlay devices, the Orlando, Fla.-based company said. The newly cleared […]
From Skyline Medical’s joint venture to Lensar receiving FDA clearance and CE Mark, here are seven medtech stories we missed this week but thought were still worth mentioning. 1. Skyline Medical launches JV deal with Helomics Skyline Medical announced in a Nov. 15 press release that it has signed a joint venture agreement with Helomics. […]
From Bioness’s new distribution deal to InBrace’s launch of new braces technology, here are 7 medtech stories we missed this week but thought were still worth mentioning. 1. Obalon receives approval to commercialize in Middle East Obalon Therapeutics announced in a May 11 press release that it has received regulatory approvals in select Middle East […]
Lensar Inc. today filed for Chapter 11 bankruptcy protection, saying it needs to reduce its debt and strengthen its balance sheet and platform for future growth. The Orlando, Fl.-based company was supported by its senior secured lender, PDL BioParhma Inc. In December 2015, healthcare and social commerce company Alphaeon bought the laser cataract treatment company for […]
Healthcare and social commerce company Alphaeon said today it closed its buy of laser cataract treatment company Lensar for $59 million. Terms of the deal were not disclosed. Lensar develops and manufactures Femtosecond Lasers Systems designed specifically for refractive cataract surgery, Irvine, Calif.-based Alphaeon said. “We are pleased to have closed the acquisition of Lensar. […]
Healthcare-focused social commerce company Alphaeon said Monday it inked an agreement to acquire all of the assets of laser cataract treatment company Lensar for $59 million. Lensar develops and manufactures Femtosecond Lasers Systems designed specifically for refractive cataract surgery, the company said. “Lensar has advanced the self-pay category of precision refractive surgery both for ophthalmologists […]
Opthalmology devices maker LensAR secured $8 million in equity funding, according to an SEC filing dated July 31, 2014.
Orlando, Fla.-based cataract surgery technology company LensAR closed an equity funding round with $10 million raised from 14 investors, regulatory documents show.
The fundraising effort, launched in December, was closed yesterday and use of the proceeds was not described, outside of an estimated $370,000 listed in payments to individuals listed as "executive officers, directors or promoters" of the company.
Orlando, Fla.-based LensAR Inc. announced the launch of a new U.K. clinical trial, evaluating the company’s laser-based lens softening system in treatment of patients with presbyopia.
The study begins with enrollment of the 1st 30 patients and will expand to more sites by the end of the year, LensAR said.
Orlando, Fla.-based medical device company LensAR Inc. touted $87 million in fundraising, mostly through a debt financing agreement, in support of its laser cataract surgery systems.
LensAR raised $27 million in private equity financing and secured up to $60 million in debt financing. The company plans to use the funds to advance commercialization worldwide and to advance development of its cataract surgery platform.